Cardlytics Stock Forecast, Price & News

Cardlytics (NASDAQ:CDLX) Frequently Asked Questions

Is Cardlytics a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cardlytics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Cardlytics stock.
View analyst ratings for Cardlytics or view top-rated stocks.

How has Cardlytics' stock been impacted by COVID-19 (Coronavirus)?

Cardlytics' stock was trading at $45.83 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CDLX shares have increased by 36.1% and is now trading at $62.36.
View which stocks have been most impacted by COVID-19.

When is Cardlytics' next earnings date?

Cardlytics is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Cardlytics.

How were Cardlytics' earnings last quarter?

Cardlytics, Inc. (NASDAQ:CDLX) released its quarterly earnings results on Tuesday, May, 4th. The company reported ($0.34) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.56) by $0.22. The business had revenue of $53 million for the quarter, compared to analysts' expectations of $51.96 million. Cardlytics had a negative net margin of 50.59% and a negative trailing twelve-month return on equity of 13.92%. Cardlytics's quarterly revenue was up 16.5% on a year-over-year basis. During the same period in the previous year, the business posted ($0.26) EPS.
View Cardlytics' earnings history.

What guidance has Cardlytics issued on next quarter's earnings?

Cardlytics updated its FY 2021 earnings guidance on Tuesday, November, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $247.10 million-$257.10 million, compared to the consensus revenue estimate of $253.46 million.

What price target have analysts set for CDLX?

6 analysts have issued 12-month price objectives for Cardlytics' stock. Their forecasts range from $100.00 to $150.00. On average, they expect Cardlytics' share price to reach $129.67 in the next twelve months. This suggests a possible upside of 107.9% from the stock's current price.
View analysts' price targets for Cardlytics or view top-rated stocks among Wall Street analysts.

Who are Cardlytics' key executives?

Cardlytics' management team includes the following people:

• Lynne Marie Laube, Chief Executive Officer & Director (LinkedIn Profile)
• Peter Davies, Head-Sales Strategy & Operations
• Andrew Christiansen, Chief Financial & Accounting Officer (LinkedIn Profile)
• Manohar Reddy Dendi, Engineering Director
• Craig Stuart Snodgrass, Chief Data Officer

What is Scott Grimes' approval rating as Cardlytics' CEO?

63 employees have rated Cardlytics CEO Scott Grimes on Glassdoor.com. Scott Grimes has an approval rating of 86% among Cardlytics' employees.

Who are some of Cardlytics' key competitors?

Some companies that are related to Cardlytics include Wix.com (WIX), Weibo (WB), Switch (SWCH), DoubleVerify (DV), Sportradar Group (SRAD), Bumble (BMBL), Internet Initiative Japan (IIJIY), KnowBe4 (KNBE), Dada Nexus (DADA), TripAdvisor (TRIP), Integral Ad Science (IAS), Chindata Group (CD), Momentive Global (MNTV), Rackspace Technology (RXT) and Sabre (SABR).
View all of CDLX's competitors.

What other stocks do shareholders of Cardlytics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardlytics investors own include NVIDIA (NVDA), Square (SQ), DocuSign (DOCU), Advanced Micro Devices (AMD), Caterpillar (CAT), Walt Disney (DIS), Alibaba Group (BABA), Trade Desk (TTD), QUALCOMM (QCOM) and Twilio (TWLO).

When did Cardlytics IPO?

(CDLX) raised $76 million in an IPO on Friday, February 9th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. BofA Merrill Lynch and J.P. Morgan served as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey, Raymond James and KeyBanc Capital Markets were co-managers.

What is Cardlytics' stock symbol?

Cardlytics trades on the NASDAQ under the ticker symbol "CDLX."

Who are Cardlytics' major shareholders?

Cardlytics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.42%), Morgan Stanley (2.81%), Baillie Gifford & Co. (2.26%), Bank of New York Mellon Corp (2.10%), Geode Capital Management LLC (1.64%) and JS Capital Management LLC (1.05%). Company insiders that own Cardlytics stock include Andrew Christiansen, Bryce Youngren, Clifford Sosin, David Leslie Adams, David Thomas Evans, John L Jr Klinck, John V Balen, John V Balen, Kirk Somers, Lynne Marie Laube, Mark A Johnson, S Aimee Lapic, Scott D Grimes, Scott D Grimes and Tony Weisman.
View institutional ownership trends for Cardlytics.

Which institutional investors are selling Cardlytics stock?

CDLX stock was sold by a variety of institutional investors in the last quarter, including FIL Ltd, Frontier Capital Management Co. LLC, Jennison Associates LLC, JS Capital Management LLC, Renaissance Technologies LLC, BlackRock Inc., Credit Suisse AG, and Cubist Systematic Strategies LLC. Company insiders that have sold Cardlytics company stock in the last year include Andrew Christiansen, Kirk Somers, Lynne Marie Laube, S Aimee Lapic, and Scott D Grimes.
View insider buying and selling activity for Cardlytics or view top insider-selling stocks.

Which institutional investors are buying Cardlytics stock?

CDLX stock was purchased by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Baillie Gifford & Co., Morgan Stanley, Pier Capital LLC, Citadel Advisors LLC, LPL Financial LLC, Wolverine Trading LLC, and Jane Street Group LLC. Company insiders that have bought Cardlytics stock in the last two years include Clifford Sosin, and John V Balen.
View insider buying and selling activity for Cardlytics or or view top insider-buying stocks.

How do I buy shares of Cardlytics?

Shares of CDLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cardlytics' stock price today?

One share of CDLX stock can currently be purchased for approximately $62.36.

How much money does Cardlytics make?

Cardlytics has a market capitalization of $2.07 billion and generates $186.89 million in revenue each year. The company earns $-55.42 million in net income (profit) each year or ($3.87) on an earnings per share basis.

How many employees does Cardlytics have?

Cardlytics employs 471 workers across the globe.

What is Cardlytics' official website?

The official website for Cardlytics is www.cardlytics.com.

Where are Cardlytics' headquarters?

Cardlytics is headquartered at 675 PONCE DE LEON AVENUE NE SUITE 6000, ATLANTA GA, 30308.

How can I contact Cardlytics?

Cardlytics' mailing address is 675 PONCE DE LEON AVENUE NE SUITE 6000, ATLANTA GA, 30308. The company can be reached via phone at (888) 798-5802 or via email at [email protected].